| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Osteosarcoma | D012516 | 50 associated lipids |
| Glioma | D005910 | 112 associated lipids |
(e,z)-farnesol
(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol
PubChem Biomolecular Interactions and Pathways
All references with (e,z)-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Supuran CT | Nanoparticles for controlled release of anti-biofilm agents WO2014130994 (A1): a patent evaluation. | 2015 | Expert Opin Ther Pat | pmid:26028186 |
| Abdel-Rhman SH et al. | Effect of Tyrosol and Farnesol on Virulence and Antibiotic Resistance of Clinical Isolates of Pseudomonas aeruginosa. | 2015 | Biomed Res Int | pmid:26844228 |
| Kostoulias X et al. | Impact of a Cross-Kingdom Signaling Molecule of Candida albicans on Acinetobacter baumannii Physiology. | 2015 | Antimicrob. Agents Chemother. | pmid:26482299 |
| Hameiri-Grossman M et al. | The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth. | 2015 | Oncotarget | pmid:26393682 |
| Lopez-Medina E et al. | Candida albicans Inhibits Pseudomonas aeruginosa Virulence through Suppression of Pyochelin and Pyoverdine Biosynthesis. | 2015 | PLoS Pathog. | pmid:26313907 |
| Katragkou A et al. | In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms. | 2015 | J. Antimicrob. Chemother. | pmid:25288679 |
| Strube-Bloss MF et al. | Extracting the Behaviorally Relevant Stimulus: Unique Neural Representation of Farnesol, a Component of the Recruitment Pheromone of Bombus terrestris. | 2015 | PLoS ONE | pmid:26340263 |
| Scheman A et al. | European Directive fragrances in natural products. | 2014 Mar-Apr | Dermatitis | pmid:24603515 |
| Neeman R et al. | Vitamin D and S-farnesylthiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation. | 2014 | Dig. Dis. Sci. | pmid:24942325 |
| Makovski V et al. | Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway. | 2014 | Cell Death Dis | pmid:25476905 |